Corgenix Medical Corporation (OTCQB: CONX), a worldwide developer and marketer of diagnostic test kits, has entered into a U.S. distribution agreement with strategic partner AXA Diagnostics Srl of Pomezia, Italy.
Under terms of the agreement, Corgenix will market AXA Diagnostics’ proprietary SkyLAB 752™ ELISA/IFA Analyzer on a non-exclusive basis in the United States.
The SkyLAB 752 is the first automated microplate processing instrument that can independently multitask performing all functions at the same time-a new feature not found on other instrumentation. The new, high-throughput ELISA (enzyme-linked immunosorbent assay) and IFA (immunofluorescence assay) platform can process up to 7 microplates or 28 IFA slides simultaneously. Due to its state-of-the-art pipetting system the SkyLAB 752 can easily process Corgenix rapid ELISA tests for significant time and cost savings to the laboratories, giving Corgenix products a significant advantage over competitive test kits with longer incubation times.
“The breakthrough technology and unique features of the SkyLAB 752 will allow us to market this instrument in conjunction with Corgenix ELISA kits and offer higher throughput and labor-saving advantages to our customers,” said Corgenix President and CEO Douglass Simpson. “We are extremely pleased that AXA Diagnostics has chosen to establish this relationship with Corgenix.”
Simpson said the SkyLAB 752 will be available for evaluation at external sites by year’s end and will be registered as a Class I Device with the FDA by Dec. 31, 2011.
AXA Diagnostics General Manager Silvio Furino said Corgenix has built a strong reputation for providing innovative healthcare products to its customers, which makes them an ideal partner for AXA Diagnostics.
“We’re excited to be establishing this strategic alliance with Corgenix, enabling the company to offer its customers a unique assay automation solution,” Furino said. “Our new SkyLAB 752 instrument gives Corgenix the ability to automate their rapid immunoassay kits that, until now, were not able to be used in conjunction with other instrumentation available in the market.”
Key differentiating features of the SkyLAB 752 analyzer allow a full microplate to be loaded in approximately eight minutes, which is about half the time of most other analyzers on the market. The SkyLAB instrument also incorporates incubation options that include: heating and shaking; the use of standard disposable pipette tips that eliminate carryover; clot detection; bubble detection; positive sample ID; and custom software that allows remote diagnostics and communication with LIS software. The SkyLAB 752 uses a state-of-the-art LED microplate reading system that allows precision, reduced maintenance and a 3.5 OD dynamic range. For more information, visit the SkyLAB 752 website at www.skylabteam.org.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.
About AXA Diagnostics Srl
AXA Diagnostics is a private company located in Pomezia, Italy that markets proprietary instrumentation and specialized diagnostic tests, with an emphasis on autoimmune in vitro diagnostic products. AXA Diagnostics sells over 300 diagnostic products through a network of distributors in Europe and other international markets. AXA Diagnostics has obtained certification for the management of its quality system according to the requirements of UNI EN ISO 13485:2004. More information on AXA Diagnostics is available at www.axadiagnostics.com.
Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factorsthat would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.